Citadel Advisors’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

Citadel Advisors’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,383	Closed	-$87	–	15576
2024 Q4	$87	Sell	12,383 -5,425	-30%	-$85	﹤0.01%	14384
2024 Q3	$356	Sell	17,808 -100	-0.6%	-$2	﹤0.01%	14041
2024 Q2	$364	Buy	17,908 +4,534	+34%	+$350	﹤0.01%	14008
2024 Q1	$2.94K	Sell	13,374 -8,831	-40%	-$2.01K	﹤0.01%	13956
2023 Q4	$2.89K	Sell	22,205 -10,624	-32%	-$1.68K	﹤0.01%	13647
2023 Q3	$3.02K	Buy	32,829 +4,819	+17%	+$392	﹤0.01%	13643
2023 Q2	$1.26K	Buy	28,010 +10,703	+62%	+$589	﹤0.01%	13956
2023 Q1	$1.64K	Buy	+17,307	New	+$2.14K	﹤0.01%	14263

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return

FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

Citadel Advisors's STLNW Position: Q1 2025 in Review

Citadel Advisors sold out of Starling Oncology, Inc. Warrant (STLNW) in Q1 2025, closing a stake of 12,383 shares — an estimated $87 sold.

Citadel Advisors first reported a position in STLNW in Q1 2023 and held it in 8 quarters. The position peaked at $3.02K in Q3 2023. 11 funds tracked by Wall St. Rank hold STLNW as of Q1 2025.

Citadel Advisors reported no remaining Starling Oncology, Inc. Warrant position as of Q1 2025 after selling out during the quarter.
Citadel Advisors sold 12,383 Starling Oncology, Inc. Warrant shares in Q1 2025, an estimated $87.
Citadel Advisors first reported a position in Starling Oncology, Inc. Warrant in Q1 2023 and held it in 8 quarters.
Citadel Advisors's Starling Oncology, Inc. Warrant position peaked at $3.02K in Q3 2023.
11 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.